VBI Vaccines

VBI Vaccines is a biopharmaceutical company focused on developing vaccine candidates for infectious diseases and aggressive cancers, utilizing innovative virus-like particle technologies.

Company Overview

VBI Vaccines is a biopharmaceutical company focused on developing vaccine candidates that mimic the natural presentation of viruses. Headquartered in Cambridge, Massachusetts, VBI Vaccines has research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel. The company aims to harness the innate power of the human immune system to target and overcome significant infectious diseases and aggressive cancers. Their innovative approach includes proprietary technologies such as the enveloped virus-like particle (eVLP) platform and the mRNA-launched eVLP (MLE) platform.

Infectious Disease Targets

VBI Vaccines is dedicated to addressing significant infectious diseases, including hepatitis B, COVID-19 and other coronaviruses, and cytomegalovirus (CMV). By employing their proprietary eVLP and MLE platform technologies, the company develops vaccine candidates designed to elicit strong immune responses. These efforts aim to combat and prevent the spread of these serious infectious diseases.

Cancer Vaccine Development

In addition to infectious diseases, VBI Vaccines is committed to developing vaccines for aggressive cancers, with a specific focus on glioblastoma (GBM). By leveraging their innovative platform technologies, the company seeks to generate effective vaccines that could potentially improve the treatment and prognosis of patients suffering from these challenging types of cancer.

Innovative Vaccine Platforms

VBI Vaccines utilizes advanced technological platforms in their vaccine development processes. The company's proprietary enveloped virus-like particle (eVLP) platform enhances the mimicking of the natural structure of viruses to stimulate strong immune responses. Additionally, the mRNA-launched eVLP (MLE) platform technology allows for the rapid development of vaccine candidates, potentially accelerating the time-to-market for new vaccines addressing urgent medical needs.

Global Research and Manufacturing

With headquarters in Cambridge, Massachusetts, and research operations in Ottawa, Canada, VBI Vaccines also operates a research and manufacturing facility in Rehovot, Israel. This global presence enables the company to conduct comprehensive research and development activities, as well as scale up production capabilities to meet global demands for their vaccine candidates.